SXTP

60 Degrees Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website 60degreespharma.com
Employees(FY) 2
ISIN US83006G1040

Performance

-2.22%

1W

-13.5%

1M

-30.37%

3M

-66.93%

6M

-77.95%

YTD

-95.19%

1Y

Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.

Advanced Technical Analysis

Technical Analysis of SXTP 2024-05-10

Overview:

In analyzing the technical indicators for SXTP over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.

Trend Indicators...

See more ...

Recent News & Updates

2024-05-15 09:55
SXTP Stock Earnings: 60 Degrees Reported Results for Q1 2024(Investorplace)
2024-05-15 01:45
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results(Globenewswire)
2024-05-07 19:59
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases(Globenewswire)
2024-05-01 19:59
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required(Globenewswire)
2024-04-02 19:58
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis(Globenewswire)
2024-03-13 19:59
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024(Globenewswire)
2024-02-19 18:59
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris(Globenewswire)
2024-02-07 18:59
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer(Globenewswire)
2024-01-30 23:00
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering(Prnewswire)
2024-01-30 22:15
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering(Globenewswire)
2024-01-29 20:45
WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering(Prnewswire)
2024-01-29 20:00
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering(Globenewswire)
2024-01-21 18:59
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting(Globenewswire)
2024-01-15 18:59
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements(Globenewswire)
2023-12-25 18:59
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024(Globenewswire)
2023-11-14 18:29
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease(Globenewswire)
2023-10-18 20:31
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston(Globenewswire)
2023-10-12 04:16
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases(Globenewswire)
2023-09-18 04:16
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements(Yahoo Finance)
2023-09-05 19:31
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-31 21:00
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV(Yahoo Finance)
2023-08-29 19:32
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity(Yahoo Finance)
2023-08-21 19:31
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria(Yahoo Finance)
2023-08-14 19:31
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov(Yahoo Finance)
2023-07-30 19:59
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects(Yahoo Finance)
2023-07-20 21:00
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)(Yahoo Finance)
2023-07-14 01:30
WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit(Yahoo Finance)
2023-07-14 00:39
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering(Yahoo Finance)
2023-07-12 01:45
WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit(Yahoo Finance)
2023-07-12 00:29
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering(Yahoo Finance)

Page 1 of 1

previousnext